CryptoWorld News reports that, according to a tweet from Bloomberg, OpenAI CEO Sam Altman stated that the company might consider investing in or subsidizing companies that heavily use its AI technology to discover new drugs or therapies, and may charge licensing fees in return.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin